Crit Care:较高和正常血压目标值对预防急性肾损伤的价值

2022-11-28 MedSci原创 MedSci原创 发表于上海

肾灌注不足是急性肾损伤(AKI)最常见的原因之一,特别是在休克和围手术期患者。预防AKI的最佳血压(BP)目标仍未确定。

肾灌注不足是急性肾损伤(AKI)最常见的原因之一,特别是在休克和围手术期患者。预防AKI的最佳血压(BP)目标仍未确定。

近日,危重病医学领域权威杂志Critical Care上发表了一篇研究文章,研究人员对现有的随机临床试验(RCT)结果进行了系统回顾和荟萃分析,以明确这一问题。

研究人员检索了Ovid Medline、EMBASE、Cochrane图书馆、SCOPUS、clinicaltrials.gov和WHO ICTRP,检索时间从数据库成立到2022年5月13日,以比较血流动力学不稳定患者(休克、心脏骤停后或手术患者)的高血压目标与正常血压的RCT。感兴趣的结果是干预后AKI发生率和肾替代治疗(RRT)率。两名研究人员独立筛选引用,并根据预定义的形式审查合格研究的全文。

该研究共纳入了12项试验,共纳入了5759名参与者,休克、非心脏和心脏手术患者分别有3282(57.0%)、1687(29.3%)和790(13.7%)例患者。通过随机效应meta分析,与作为正常血压的较低平均动脉血压(MAP)目标值相比,在休克(RR[95%CI]=1.10[0.93, 1.29])、心脏手术(RR [95%CI]=0.87[0.73, 1.03])和非心脏手术患者(RR [95%CI]=1.25[0.98, 1.60])中,较高的平均动脉血压(MAP)目标值对AKI发生率没有显著影响。然而,在既往伴有高血压的休克患者中,以MAP高于70 mmHg为目标值可显著降低RRT风险,RR [95%CI]=1.20 [1.03, 1.41],p<0.05。

由此可见,在休克或围手术期患者中,较高的MAP目标值可能并不优于正常血压,但既往伴有高血压的休克患者除外。需要进一步的研究来评估较高MAP目标值对在常见的血流动力学不稳定的高血压患者中预防AKI的作用。

原始出处:

Phu Nguyen Trong Tran.et al.Higher blood pressure versus normotension targets to prevent acute kidney injury: a systematic review and meta-regression of randomized controlled trials.Critical Care.2022.https://cardiab.biomedcentral.com/articles/10.1186/s12933-022-01692-5

版权声明:
本网站所有内容来源注明为“梅斯医学”或“MedSci原创”的文字、图片和音视频资料,版权均属于梅斯医学所有。非经授权,任何媒体、网站或个人不得转载,授权转载时须注明来源为“梅斯医学”。其它来源的文章系转载文章,或“梅斯号”自媒体发布的文章,仅系出于传递更多信息之目的,本站仅负责审核内容合规,其内容不代表本站立场,本站不负责内容的准确性和版权。如果存在侵权、或不希望被转载的媒体或个人可与我们联系,我们将立即进行删除处理。
在此留言
评论区 (4)
#插入话题
  1. [GetPortalCommentsPageByObjectIdResponse(id=2103124, encodeId=f664210312495, content=结合临床,积极管理血压, beContent=null, objectType=article, channel=null, level=null, likeNumber=32, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=a5281475204, createdName=delianjihui, createdTime=Mon Nov 28 18:27:12 CST 2022, time=2022-11-28, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2103123, encodeId=116a2103123da, content=转发学习, beContent=null, objectType=article, channel=null, level=null, likeNumber=33, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=a5281475204, createdName=delianjihui, createdTime=Mon Nov 28 18:26:50 CST 2022, time=2022-11-28, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2103122, encodeId=16bb2103122be, content=感谢分享, beContent=null, objectType=article, channel=null, level=null, likeNumber=33, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=a5281475204, createdName=delianjihui, createdTime=Mon Nov 28 18:26:47 CST 2022, time=2022-11-28, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2103121, encodeId=2f18210312187, content=学习受益, beContent=null, objectType=article, channel=null, level=null, likeNumber=26, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=a5281475204, createdName=delianjihui, createdTime=Mon Nov 28 18:26:42 CST 2022, time=2022-11-28, status=1, ipAttribution=)]
    2022-11-28 delianjihui

    结合临床,积极管理血压

    0

  2. [GetPortalCommentsPageByObjectIdResponse(id=2103124, encodeId=f664210312495, content=结合临床,积极管理血压, beContent=null, objectType=article, channel=null, level=null, likeNumber=32, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=a5281475204, createdName=delianjihui, createdTime=Mon Nov 28 18:27:12 CST 2022, time=2022-11-28, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2103123, encodeId=116a2103123da, content=转发学习, beContent=null, objectType=article, channel=null, level=null, likeNumber=33, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=a5281475204, createdName=delianjihui, createdTime=Mon Nov 28 18:26:50 CST 2022, time=2022-11-28, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2103122, encodeId=16bb2103122be, content=感谢分享, beContent=null, objectType=article, channel=null, level=null, likeNumber=33, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=a5281475204, createdName=delianjihui, createdTime=Mon Nov 28 18:26:47 CST 2022, time=2022-11-28, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2103121, encodeId=2f18210312187, content=学习受益, beContent=null, objectType=article, channel=null, level=null, likeNumber=26, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=a5281475204, createdName=delianjihui, createdTime=Mon Nov 28 18:26:42 CST 2022, time=2022-11-28, status=1, ipAttribution=)]
    2022-11-28 delianjihui

    转发学习

    0

  3. [GetPortalCommentsPageByObjectIdResponse(id=2103124, encodeId=f664210312495, content=结合临床,积极管理血压, beContent=null, objectType=article, channel=null, level=null, likeNumber=32, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=a5281475204, createdName=delianjihui, createdTime=Mon Nov 28 18:27:12 CST 2022, time=2022-11-28, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2103123, encodeId=116a2103123da, content=转发学习, beContent=null, objectType=article, channel=null, level=null, likeNumber=33, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=a5281475204, createdName=delianjihui, createdTime=Mon Nov 28 18:26:50 CST 2022, time=2022-11-28, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2103122, encodeId=16bb2103122be, content=感谢分享, beContent=null, objectType=article, channel=null, level=null, likeNumber=33, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=a5281475204, createdName=delianjihui, createdTime=Mon Nov 28 18:26:47 CST 2022, time=2022-11-28, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2103121, encodeId=2f18210312187, content=学习受益, beContent=null, objectType=article, channel=null, level=null, likeNumber=26, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=a5281475204, createdName=delianjihui, createdTime=Mon Nov 28 18:26:42 CST 2022, time=2022-11-28, status=1, ipAttribution=)]
    2022-11-28 delianjihui

    感谢分享

    0

  4. [GetPortalCommentsPageByObjectIdResponse(id=2103124, encodeId=f664210312495, content=结合临床,积极管理血压, beContent=null, objectType=article, channel=null, level=null, likeNumber=32, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=a5281475204, createdName=delianjihui, createdTime=Mon Nov 28 18:27:12 CST 2022, time=2022-11-28, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2103123, encodeId=116a2103123da, content=转发学习, beContent=null, objectType=article, channel=null, level=null, likeNumber=33, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=a5281475204, createdName=delianjihui, createdTime=Mon Nov 28 18:26:50 CST 2022, time=2022-11-28, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2103122, encodeId=16bb2103122be, content=感谢分享, beContent=null, objectType=article, channel=null, level=null, likeNumber=33, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=a5281475204, createdName=delianjihui, createdTime=Mon Nov 28 18:26:47 CST 2022, time=2022-11-28, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2103121, encodeId=2f18210312187, content=学习受益, beContent=null, objectType=article, channel=null, level=null, likeNumber=26, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=a5281475204, createdName=delianjihui, createdTime=Mon Nov 28 18:26:42 CST 2022, time=2022-11-28, status=1, ipAttribution=)]
    2022-11-28 delianjihui

    学习受益

    0

相关资讯

JAMA:ICU中老年患者升压治疗的血压目标,高点好还是低点好?

重症监护病房(ICU)的患者经常使用升压药物,以避免低血压相关心肌损伤、肾损伤和死亡。然而,升压药物会降低血管收缩血管床的血流量,并对心脏、代谢、微生物群和免疫功能产生影响。因此,平衡低血压风险和升压

Heart:2型糖尿病患者血压靶标

英国学者们探讨了血压与2型糖尿病患者入院风险的相关性,结果表明,2型糖尿病患者的血压在133–141/76–80 mm Hg时,其心血管住院风险最低。上述血压目标值与最近美国糖尿病学会(ADA)基于随机对照研究而推荐的血压目标值140/80 mm Hg保持一致。 该研究纳入4704例2型糖尿病患者。主要转归为心血管住院。利用Cox模型评估每一血压水平患者的校正相对风险值。利用限制三次样条模型进一